期刊
SCIENTIFIC REPORTS
卷 6, 期 -, 页码 -出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/srep37889
关键词
-
资金
- Ministry of Health, Labour and Welfare, Japan [H20-ninchisho-ippan-004]
- Japan Agency for Medical Research and Development [H25-ninchisho-ippann-004]
- Japan Society for the Promotion of Science [22221004, 15K15085, 25461281]
- Grants-in-Aid for Scientific Research [15H04298, 15K15085, 25461281] Funding Source: KAKEN
In the mitochondria-mediated vicious cycle of Alzheimer's disease (AD), intracellular amyloid beta (A beta) induces mitochondrial dysfunction and reactive oxygen species, which further accelerate A beta accumulation. This vicious cycle is thought to play a pivotal role in the development of AD, although the molecular mechanism remains unclear. Here, we examined the effects of human mitochondrial transcriptional factor A (hTFAM) on the pathology of a mouse model of AD (3xTg-AD), because TFAM is known to protect mitochondria from oxidative stress through maintenance of mitochondrial DNA (mtDNA). Expression of hTFAM significantly improved cognitive function, reducing accumulation of both 8-oxoguanine, an oxidized form of guanine, in mtDNA and intracellular A beta in 3xTg-AD mice and increasing expression of transthyretin, known to inhibit A beta aggregation. Next, we found that AD model neurons derived from human induced pluripotent stem cells carrying a mutant PSEN1((P117L)) gene, exhibited mitochondrial dysfunction, accumulation of 8-oxoguanine and single-strand breaks in mtDNA, and impaired neuritogenesis with a decreased expression of transthyretin, which is known to be downregulated by oxidative stress. Extracellular treatment with recombinant hTFAM effectively suppressed these deleterious outcomes. Moreover, the treatment increased expression of transthyretin, accompanied by reduction of intracellular A beta. These results provide new insights into potential novel therapeutic targets.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据